Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01815086 · ClinicalTrials.gov registry record · Phase 1
Radioimmunoimaging of Light Chain (AL) Amyloidosis
A Phase 1 study, sponsored by University of Tennessee.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01815086 is a Phase 1 study that has completed, run by University of Tennessee. The registered enrollment target is 30 participants.
The verdict
NCT01815086, a Phase 1 study, has completed, sponsored by University of Tennessee.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive monoclonal antibody (mAb) to document the presence and distribution of amyloid deposits by PET/CT imaging in patients with AL amyloidosis.
Interventions
- BIOLOGICAL Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-12 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01815086
The ClinicalTrials.gov registry entry for NCT01815086 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Tennessee, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg) is the first listed.
NCT01815086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01815086 about?
NCT01815086 is a clinical study titled "Radioimmunoimaging of Light Chain (AL) Amyloidosis". The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive monoclonal antibody (mAb) to document the presence and distribution of amyloid deposits by PET/CT imaging in patients with AL amyloidosis.
What is the current status of trial NCT01815086?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2008-12. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01815086?
The interventions under investigation include: Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01815086?
This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.